CTOs on the Move

ArcherDX

www.archerdx.com

 
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.archerdx.com
  • 2477 55th Street Suite 202
    Boulder, CO USA 80301
  • Phone: 303.357.9001

Executives

Name Title Contact Details

Funding

ArcherDX raised $35M on 03/20/2018
ArcherDX raised $60M on 05/15/2019
ArcherDX raised $55M on 12/17/2019

Similar Companies

Unigene Laboratories

Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides

Mirus Bio

Mirus Bio is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Knopp Neurosciences

Knopp Neurosciences is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QUATRx Pharmaceuticals Company

QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advaxis

Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. Its Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. The company’s platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. It has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. The company’s products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA for the treatment of prostate cancer; and ADXS-cHER2 for the treatment of overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.